Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions

Castration Resistant Prostate CancerCastration Sensitive Prostate CancerProstate Adenocarcinoma

Interventions

DRUG

Piflufolastat

Given IV

PROCEDURE

PSMA PET/CT Scan

Undergo PSMA PET/CT

PROCEDURE

PSMA PET/MRI scan

Undergo PET/MRI

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Electronic Health Record Review

Ancillary studies

Trial Locations (1)

RECRUITING

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

Oregon Health and Science University

OTHER

collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT05919329 - Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy | Biotech Hunter | Biotech Hunter